BioPharmSignal logoBioPharmSignal

Biotech News

Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers

Fennec Pharmaceuticals Inc. (FENC)Fennec Pharmaceuticals Inc.Company update

– Administration of PEDMARK ® Approximately Six Hours After Cisplatin was Shown to Be Safe & Easily Integrated into Care for Adults with Head & Neck Cancers (HNC) – – Early Signals of Hearing Preservation Highlight the Potential of PEDMARK ® to Address Cisplatin-Induced Hearing Loss, a Critical

Related news

FENCFennec Pharmaceuticals Inc.2026-08-11 11:01 EST

Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

FENCFennec Pharmaceuticals Inc.2026-08-05 11:01 EST

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

RVMDRevolution Medicines2026-07-02 12:00 EST

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

IDYAIDEAYA Biosciences2026-06-15 10:00 EST

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

GNLXGenelux2026-06-30 12:00 EST

Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer

RVMDRevolution Medicines2026-06-23 12:00 EST

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

IDYAIDEAYA Biosciences2026-07-27 10:00 EST

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

FATEFate Therapeutics2026-07-06 12:30 EST

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

View all latest news

Fennec Pharmaceuticals Inc.

Ototoxicity Prevention Company Fennec Pharmaceuticals commercializes PEDMARK, a sodium thiosulfate formulation designed to reduce permanent hearing loss caused by cisplatin chemotherapy. Pediatric Commercial Foundation PEDMARK is approved for pediatric patients with localized, non-metastatic solid tumors. Fennec supports adoption through...

Recent company news

FENCFennec Pharmaceuticals Inc.2026-08-11 11:01 EST

Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

FENCFennec Pharmaceuticals Inc.2026-08-05 11:01 EST

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

FENCFennec Pharmaceuticals Inc.2026-06-15 10:00 EST

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

FENCFennec Pharmaceuticals Inc.2026-06-10 20:30 EST

Fennec Announces Results of Annual Meeting

FENCFennec Pharmaceuticals Inc.2026-05-21 22:01 EST

Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting

Stock data

Close
11.29 USD
Market cap
346.68M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States